小剂量沙利度胺联合化疗治疗多发性骨髓瘤临床观察  

The clinical study of thalidomide combining with chemotherapy in treating of multiple myeloma

作　　者：郝鲁梅[1] 吴弘英[1] 兰巧玲[1] 王雷[1] 马树沛[1] 

机构地区：[1]山东省青岛市市立医院东院血液科,266071

出　　处：《中国现代医药杂志》2010年第6期33-35,共3页Modern Medicine Journal of China

摘　　要：目的观察小剂量沙利度胺联合化疗治疗多发性骨髓瘤（MM）的疗效及不良反应。方法 20例初治和5例复发难治MM患者,采用小剂量沙利度胺（100~200mg/d）联合VTD、MP方案治疗。结果 20例初治MM患者中,CR3例,PR12例,有效率为75%。5例复发难治患者CR1例,PR2例,有效率为60%。不良反应主要有便秘、肢端麻木感、嗜睡、乏力等,但均较轻微。结论小剂量沙利度胺＋联合化疗治疗多发性骨髓瘤,无论是初治还是复发患者均有较好疗效且耐受性好。Objective To explore the outcome and side-effects in patients with multiple myeloma （MM） treated with low dose thalidomide and combined chemotherapy. Methods 20 patients with untreated MM and 5 patients with relapse or refractory MM were treated with low dose thalidomide （100~200mg/d） combining MP（Melphalan＋Prednisong） or VTD（Vindesine ＋ Pirarubicin＋Dexamethasone） regimen. Results In the 20 untreated MM cases,3 obtained complete remission （CR） and 12 obtained partial remission （PR）.The efficiency was 75%.In the 5 relapse or refractory cases,1 obtained CR,2 obtained PR. The efficiency was 60%. The major toxicities consisted of constipation, peripheral neuropathy,somnolence and fatigue. Conclusion The low dose thalidomide combined combination chemotherapy is effective and tolerable in treating both untreated MM and relapse or refractory MM.

关 键 词：沙利度胺 多发性骨髓瘤 化疗 

分 类 号：R733.3[医药卫生—肿瘤]